22 February 2021
Visiongain has published a new report on Short Bowel Syndrome Market Report 2021-2031: Forecasts By Treatment (Nutritional Support, Medications, Surgery, Intestinal Transplant, and Others), By Type (Small Intestine, and Large Intestine), By Patient Demographics (Adults, Geriatric, Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Short Bowel Syndrome was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Short Bowel Syndrome and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.
COVID-19 Impact on Short Bowel Syndrome
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Short Bowel Syndrome. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Increasing Prevalence of short bowel syndrome around the World
The burden of short bowel syndrome is increasing very rapidly around the world however it is a rare disease, and it is expected to continuously rise over the forecast period. Short bowel syndrome occurs due to surgery for removal of a portion of the small intestine, cancer and damage to the intestines caused by cancer treatment, crohn's disease, and among others. The increasing prevalence of short bowel syndrome is creating a huge demand for the short bowel syndrome therapeutics for the treatment of short bowel syndrome. Due to which increasing prevalence of short bowel syndrome around the world is working as a driver for the pain management therapeutics market.
Increasing geriatric population around the world
An increasing in geriatric population is suffering from short bowel syndrome. All regions are facing a huge increase in the number of geriatric populations. For instance: According to the United Nations, Department of Economic and Social Affairs, the Population Division geriatric population (persons aged 65 or over) was 702.9 million in 2019. Geriatric population is more prone to short bowel syndrome. Rapid increase in the number of the geriatric population around the globe is also increasing demand for short bowel syndrome around the world. Due to which an increasing geriatric population around the world is working as a driver for the short bowel syndrome.
Increasing Focus on Advance Therapeutics
Researchers and pharmaceutical manufacturers from all over the world are increasing their focus on research and development for advance therapeutics for the treatment of short bowel syndrome and are taking required steps to create or advance therapeutics for short bowel syndrome treatment. Researcher and pharmaceutical manufacture in developing nations are undergoing regress research and development from the last few years. Increasing focus on advanced therapeutics for short bowel syndrome treatment is expected to increase the number of advanced therapeutics for short bowel syndrome treatment which is expected to create new opportunities for short bowel syndrome.
Top companies (Shire plc (Takeda Pharmaceutical Company Limited), Zealand Pharma A/S, Sancilio & Company, Inc.) constitute more than XX% share of the global Short Bowel Syndrome. Other companies profiled in the report include: OxThera, Nutrinia Ltd., Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc. (Pfizer Inc.), Merck KGaA, Naia Pharmaceuticals, Inc. Some of the key developments are listed below:
● In 2019, Takeda Pharmaceuticals, U.S.A., Inc. received U.S. Food and Drug Administration (FDA) approval for GATTEX (teduglutide). GATTEX (teduglutide) is specially designed for the treatment of pediatric patients 1 year of age and older with short bowel syndrome (SBS). The approval will help the company to expand its short bowel syndrome portfolio and widened revenue generation from market focused product portfolio.
● In 2020, VectivBio has received $35 million in financing from OrbiMed, Tekla Healthcare Investors, Versant Ventures, Novo Holdings, BPI France, Inserm Transfert Initiative and Cowen Healthcare Investments. The company is a clinical-stage biotechnology company, and developing apraglutide (under Phase 2 trials) for treatment of short bowel syndrome. The new financing will help the company to speed up development of the market focus product.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.